December 2024
·
30 Reads
Drosophila melanogaster, commonly known as the fruit fly, has been extensively used as a model organism to investigate many aspects of human diseases. Drosophila is also emerging as an exciting tool in the drug discovery process for disease conditions such as neurodegenerative disorders. The relatively short lifespan of the fly, the ease of genetic manipulation, and the ability to model many aspects of neurodegenerative diseases combine to make Drosophila a desirable preclinical system for new drug screening and discovery. In recent years, large-scale genome analysis, high-throughput screening (HTS), and the development and use of behavioral, physiological, or cellular assays in Drosophila have contributed to exploring new pathological mechanisms underlying neurodegenerative diseases. In this book chapter, we will discuss the benefits of using Drosophila as a model organism in understanding the most common neurodegenerative diseases in humans including Alzheimer’s, Parkinson’s, Huntington’s diseases, and amyotrophic lateral sclerosis (ALS). We will focus on the advantages of utilizing flies in drug discovery and screening purposes highlighting in detail different methods and protocols that are practiced in research settings in quantifying disease-related phenotypes. Furthermore, we will detail the various tools and approaches used in flies that yield information that can inform drug discovery and disease treatment approaches. We hope that this book chapter will provide a platform for understanding the purpose of using Drosophila as a disease model and different molecular and genetic approaches applied to flies in drug discovery.